Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of HLD200 in Children and Adolescents with ADHD
NCT01907360Phase 2Completed
- Sponsor
- Ironshore Pharmaceuticals
- Start
- Aug 2013
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of methylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by Ironshore Pharmaceuticals. Started Aug 2013; status: completed.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT01907360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01907360.